Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems-Reference-Cited by-同舟云学术

Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems

Published:2011-02 Issue:3 Volume:250 Page:312-321
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Fanzani Alessandro,Zanola Alessandra,Rovetta Francesca,Rossi Stefania,Aleo Maria Francesca

Funder

University of Brescia

“Siderurgica Leonessa S.r.l.” Brescia-Italy

“Associazione Amici per il Cuore-ONLUS”, Chiari (Brescia)-Italy

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference64 articles.

1. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome;Acharyya;Clin. Cancer Res.,2007

2. Localized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway;Aucello;Autophagy,2009

3. Cisplatin: a review of toxicities and therapeutic applications;Barabas;Vet. Comp. Oncol.,2008

4. Regulation of skeletal muscle proteolysis by amino acids;Bechet;J. Ren. Nutr.,2005

5. Lysosomal proteolysis in skeletal muscle;Bechet;Int. J. Biochem. Cell Biol.,2005

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms of cancer cachexia. Role of exercise training;Molecular Aspects of Medicine;2024-10

2. The combination of quercetin and leucine synergistically improves grip strength by attenuating muscle atrophy by multiple mechanisms in mice exposed to cisplatin;PLOS ONE;2023-09-12

3. Polysaccharide of Ganoderma lucidum Ameliorates Cachectic Myopathy Induced by the Combination Cisplatin plus Docetaxel in Mice;Microbiology Spectrum;2023-06-15

4. Chemotherapy-Induced Molecular Changes in Skeletal Muscle;Biomedicines;2023-03-15

5. Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives;Cancers;2022-11-02